Arcus Biosciences (RCUS) has an average rating of buy and price targets ranging from $45 to $100, according to analysts polled by Capital IQ. (MT Newswires...
Arcus Biosciences (RCUS) has an average rating of buy and price targets ranging from $45 to $100, according to analysts polled by Capital IQ. (MT Newswires...
Arcus Biosciences (RCUS) has an average investment rating of buy perform among analysts polled by Capital IQ, with a price target range of $45 to $100. (MT...
Arcus Biosciences (RCUS) has an average rating of buy and price targets ranging from $45 to $100, according to analysts polled by Capital IQ. (MT Newswires...
| Address | 3928 Point Eden Way Hayward, California 94545 |
| Phone | +1.510.694.6200 |
| Number of Employees | 108 |
| Recent SEC Filing | 11/18/2021 8-K |
| Chairman & Chief Executive Officer | Terry J. Rosen |
| President & Director | Juan Carlos Jaen |
| Chief Operating Officer & Director | Jennifer Jarrett |
| Chief Financial & Accounting Officer | Robert C. Goeltz |
| Price Open | $45.03 |
| Previous Close | $43.80 |
| 52 Week Range | $22.36 - 49.10 |
| Market Capitalization | $3.1 B |
| Shares Outstanding | 70.2 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 02/23/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$4.10 |
| Beta vs. S&P 500 | N/A |
| Revenue | $8.4 M |
| Net Profit Margin | -735.12% |
| Return on Equity | -48.12% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
